ApoB vs LDL Cholesterol: The Number That Predicts Risk

The standard lipid panel is a 1970s instrument still doing 2020s work. It reports total cholesterol, HDL cholesterol, triglycerides, and an LDL cholesterol value that in most laboratories is still calculated rather than measured. It is cheap, it is universal, and for a large fraction of the population it is good enough. For the population reading this site, it is frequently misleading, and the reason is a distinction between cargo and vehicles.

Cargo Versus Vehicles

Cholesterol does not dissolve in plasma. It travels inside lipoprotein particles, and every particle capable of depositing cholesterol in an arterial wall carries exactly one molecule of apolipoprotein B on its surface. That includes LDL, VLDL, IDL, chylomicron remnants, and lipoprotein(a). One particle, one ApoB. Measure ApoB and you have counted the atherogenic particles in circulation.

LDL cholesterol answers a different question: how much cholesterol mass is being carried inside the LDL fraction. That is a measure of cargo. If your particles are large and well loaded, you can carry a given cholesterol mass in relatively few of them. If your particles are small and depleted, you need many more particles to carry the same cargo. Two people with an identical LDL-C of 110 mg/dL can differ substantially in how many particles are actually circulating.

This matters because the initiating step in atherosclerosis is particle-dependent. A lipoprotein particle crosses the endothelium, is retained by binding to arterial wall proteoglycans, becomes modified, and triggers the inflammatory cascade that builds a plaque. The probability of that sequence scales with how many particles are presented to the endothelium, not with how much cholesterol each one happens to be carrying. Sniderman has argued this case for years through discordance analysis, and the accumulated evidence has moved most lipid specialists toward it.

What the Evidence Shows

Marston and colleagues analysed apolipoprotein B-containing lipoproteins and myocardial infarction risk and found that ApoB captured essentially the full association, with triglyceride and cholesterol content adding little predictive value once particle number was accounted for. Ference and colleagues, using genetic variants that lower triglycerides through LPL and lower LDL-C through LDLR as natural randomisation experiments, found that clinical benefit tracked the change in ApoB rather than the change in either lipid fraction. That is a powerful design, because genetic allocation is not confounded by lifestyle in the way observational cohorts are.

The practical translation is straightforward. When ApoB and LDL-C agree, either one will do. When they disagree, decisions should follow ApoB. Guidelines have moved in this direction, with major lipid guidance now listing ApoB as a risk-enhancing measurement and, in several European documents, as a preferred target in people with high triglycerides, diabetes, obesity, or very low LDL-C on treatment.

Why Discordance Is Common in This Population

Discordance is not a rare curiosity. It clusters in a specific metabolic phenotype, and that phenotype is over-represented among enhanced athletes.

The oral androgen row deserves particular attention. The lipid shift produced by 17-alpha-alkylated compounds is not subtle and it is not a laboratory artefact. HDL cholesterol can fall by half or more, ApoB rises, and the change is often accompanied by rising blood pressure and adverse effects on the liver. Baggish and colleagues documented the broader cardiovascular consequences of long-term illicit androgen use, and the lipid profile is one of the clearest mechanistic links. Anyone using these compounds who is not measuring ApoB is choosing not to see the most relevant number.

How to Use the Test

ApoB is measured directly by immunoassay, is standardised across laboratories, and does not require fasting. It costs little more than a standard panel. Reasonable practice is to draw it alongside a lipid panel, lipoprotein(a) at least once in a lifetime, and a marker of inflammation, and to interpret the result in the context of overall cardiovascular risk rather than against a population reference range.

Broad orientation, not a target for any individual: population median ApoB sits somewhere near 100 mg/dL in Western adults, values around 80 mg/dL correspond roughly to the LDL-C thresholds used for primary prevention, and secondary prevention targets in guideline documents run substantially lower. Where you personally should sit depends on your absolute risk, your family history, your lipoprotein(a) status, and whether imaging such as a coronary artery calcium score shows existing disease. That is a conversation with a physician, not a number to copy from an article.

What is reasonable to say generally is that ApoB responds to the same things LDL-C does. Reduced saturated fat intake, increased viscous fibre, weight loss where relevant, and aerobic training all lower it modestly. Statins, ezetimibe, PCSK9 inhibitors and bempedoic acid lower it substantially. Discontinuing oral androgens reverses a large part of the drug-induced component, usually within weeks to a few months.

The Framing I Use

Under the Tony Huge Laws of Biochemistry Physics, this is chain optimisation. You cannot optimise a system by measuring the wrong link in the chain. Cholesterol mass is downstream bookkeeping. Particle count is the variable that actually drives the pathological process at the artery wall, and if you are going to spend money on lab work, spend it on the measurement that sits closest to the mechanism.

The uncomfortable part is that the people who most need this number are the ones most likely to dislike the answer. If you are running compounds that crush HDL and raise ApoB, testing will tell you something you would rather not know. That is precisely the argument for testing.

Where This Fits in the Bigger Picture

Monitoring is the part of enhancement that nobody posts about, and it is the part that decides how long you get to keep doing this. Testing gives you a feedback loop; without one you are guessing with your organs. Start with the Enhanced Athlete Protocol bloodwork guide, then work through the full protocol hub to see how testing, training, nutrition and recovery connect. If you are early in this, the beginners page is the right entry point.

See also the nutrition pillar for dietary levers on lipids and the hormone pillar for how androgen choice interacts with the lipid profile.

Frequently Asked Questions

What is ApoB?

Apolipoprotein B is a structural protein found on the surface of every lipoprotein particle capable of causing atherosclerosis, including LDL, VLDL, IDL, remnant particles and lipoprotein(a). Because each of these particles carries exactly one ApoB molecule, measuring ApoB in blood gives a direct count of atherogenic particles rather than a measure of the cholesterol they carry.

Is ApoB better than LDL cholesterol?

For predicting cardiovascular events, the evidence favours ApoB. Analyses including Mendelian randomisation studies suggest that risk tracks particle number, and that once ApoB is accounted for, LDL cholesterol and triglyceride levels add relatively little. The two measurements usually agree; ApoB is most valuable in the situations where they do not, such as high triglycerides, insulin resistance, or very low measured LDL-C.

Do I need to fast for an ApoB test?

No. ApoB is measured directly by immunoassay and is not meaningfully affected by a recent meal, which is one of its practical advantages over a calculated LDL cholesterol value. Follow whatever instructions the ordering laboratory or physician gives, since other tests drawn at the same time may have fasting requirements.

Does anabolic steroid use raise ApoB?

Oral 17-alpha-alkylated androgens in particular are associated with pronounced suppression of HDL cholesterol and unfavourable changes in atherogenic particles, and long-term illicit androgen use has been linked to measurable cardiovascular harm in published research. Injectable testosterone at replacement doses generally has smaller lipid effects than oral compounds, but the direction and size of any change varies between individuals, which is the reason to measure rather than assume.

Who should get an ApoB test?

It is reasonable for anyone assessing cardiovascular risk, and it is particularly informative for people with high triglycerides, low HDL cholesterol, insulin resistance, obesity, diabetes, a family history of early heart disease, or any history of androgen use. If you are only going to add one marker to a standard lipid panel, this is generally the highest-yield choice.